» Articles » PMID: 34311771

MEK Inhibition Ameliorates Social Behavior Phenotypes in a Spred1 Knockout Mouse Model for RASopathy Disorders

Overview
Journal Mol Autism
Publisher Biomed Central
Date 2021 Jul 27
PMID 34311771
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: RASopathies are a group of disorders that result from mutations in genes coding for proteins involved in regulating the Ras-MAPK signaling pathway, and have an increased incidence of autism spectrum disorder (ASD). Legius syndrome is a rare RASopathy caused by loss-of-function mutations in the SPRED1 gene. The patient phenotype is similar to, but milder than, Neurofibromatosis type 1-another RASopathy caused by loss-of-function mutations in the NF1 gene. RASopathies exhibit increased activation of Ras-MAPK signaling and commonly manifest with cognitive impairments and ASD. Here, we investigated if a Spred1-/- mouse model for Legius syndrome recapitulates ASD-like symptoms, and whether targeting the Ras-MAPK pathway has therapeutic potential in this RASopathy mouse model.

Methods: We investigated social and communicative behaviors in Spred1-/- mice and probed therapeutic mechanisms underlying the observed behavioral phenotypes by pharmacological targeting of the Ras-MAPK pathway with the MEK inhibitor PD325901.

Results: Spred1-/- mice have robust increases in social dominance in the automated tube test and reduced adult ultrasonic vocalizations during social communication. Neonatal ultrasonic vocalization was also altered, with significant differences in spectral properties. Spred1-/- mice also exhibit impaired nesting behavior. Acute MEK inhibitor treatment in adulthood with PD325901 reversed the enhanced social dominance in Spred1-/- mice to normal levels, and improved nesting behavior in adult Spred1-/- mice.

Limitations: This study used an acute treatment protocol to administer the drug. It is not known what the effects of longer-term treatment would be on behavior. Further studies titrating the lowest dose of this drug that is required to alter Spred1-/- social behavior are still required. Finally, our findings are in a homozygous mouse model, whereas patients carry heterozygous mutations. These factors should be considered before any translational conclusions are drawn.

Conclusions: These results demonstrate for the first time that social behavior phenotypes in a mouse model for RASopathies (Spred1-/-) can be acutely reversed. This highlights a key role for Ras-MAPK dysregulation in mediating social behavior phenotypes in mouse models for ASD, suggesting that proper regulation of Ras-MAPK signaling is important for social behavior.

Citing Articles

Gene expression differences in the olfactory bulb associated with differential social interactions and olfactory deficits in Pax6 heterozygous mice.

Daems C, Baz E, DHooge R, Callaerts-Vegh Z, Callaerts P Biol Open. 2025; 14(2).

PMID: 39902612 PMC: 11832127. DOI: 10.1242/bio.061647.


Social Communication in Ras Pathway Disorders: A Comprehensive Review From Genetics to Behavior in Neurofibromatosis Type 1 and Noonan Syndrome.

Siqueiros-Sanchez M, Serur Y, McGhee C, Smith T, Green T Biol Psychiatry. 2024; 97(5):461-498.

PMID: 39366539 PMC: 11805629. DOI: 10.1016/j.biopsych.2024.09.019.


Impact of pathogenic variants of the Ras-mitogen-activated protein kinase pathway on major white matter tracts in the human brain.

Siqueiros-Sanchez M, Dai E, McGhee C, McNab J, Raman M, Green T Brain Commun. 2024; 6(4):fcae274.

PMID: 39210910 PMC: 11358645. DOI: 10.1093/braincomms/fcae274.


Human Vault RNAs: Exploring Their Potential Role in Cellular Metabolism.

Taube M, Lisiak N, Toton E, Rubis B Int J Mol Sci. 2024; 25(7).

PMID: 38612882 PMC: 11012908. DOI: 10.3390/ijms25074072.


Impact of trametinib on the neuropsychological profile of NF1 patients.

Lalancette E, Cantin E, Routhier M, Mailloux C, Bertrand M, Kiaei D J Neurooncol. 2024; 167(3):447-454.

PMID: 38443693 DOI: 10.1007/s11060-024-04624-3.


References
1.
Weiss B, Wolters P, Plotkin S, Widemann B, Tonsgard J, Blakeley J . NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021; 39(7):797-806. PMC: 8078274. DOI: 10.1200/JCO.20.02220. View

2.
Payne J, Barton B, Ullrich N, Cantor A, Hearps S, Cutter G . Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1. Neurology. 2016; 87(24):2575-2584. PMC: 5207004. DOI: 10.1212/WNL.0000000000003435. View

3.
Stivaros S, Garg S, Tziraki M, Cai Y, Thomas O, Mellor J . Randomised controlled trial of simvastatin treatment for autism in young children with neurofibromatosis type 1 (SANTA). Mol Autism. 2018; 9:12. PMC: 5824534. DOI: 10.1186/s13229-018-0190-z. View

4.
Petrella L, Cai Y, Sereno J, Goncalves S, Silva A, Castelo-Branco M . Brain and behaviour phenotyping of a mouse model of neurofibromatosis type-1: an MRI/DTI study on social cognition. Genes Brain Behav. 2016; 15(7):637-46. PMC: 5603718. DOI: 10.1111/gbb.12305. View

5.
Plasschaert E, Descheemaeker M, Van Eylen L, Noens I, Steyaert J, Legius E . Prevalence of Autism Spectrum Disorder symptoms in children with neurofibromatosis type 1. Am J Med Genet B Neuropsychiatr Genet. 2014; 168B(1):72-80. DOI: 10.1002/ajmg.b.32280. View